Advertisement

Endocrine

, Volume 59, Issue 1, pp 213–217 | Cite as

Palbociclib inhibits proliferation of human adrenocortical tumor cells

  • Chiara Fiorentini
  • Martina Fragni
  • Guido A. M. Tiberio
  • Diego Galli
  • Elisa Roca
  • Valentina Salvi
  • Daniela Bosisio
  • Cristina Missale
  • Massimo Terzolo
  • Maurizio Memo
  • Alfredo Berruti
  • Sandra Sigala
Research Letter

Introduction

Adrenocortical cancer (ACC) is a rare malignant tumor [1]. Pharmacological therapy is based on mitotane administered alone or in association with the EDP regimen (etoposide, doxorubicin, and cisplatin) [1]. However, the prognosis of ACC patients not amenable to surgery still remains poor and newer treatment strategies are needed [2]. Drugs targeting cell cycle could be a relevant new therapeutic approach for patients with advanced ACC [3].

Cell cycle is controlled by several key proteins, including CDKs (cyclin-dependent kinases), which are the target of recently discovered cell-cycle checkpoint inhibitors [4]. Palbociclib is a CDK4/6-inhibitor that is active against a broad range of tumors and has an acceptable toxicity, being neutropenia being the most relevant side effect [5]. This drug is actually approved in the management of locally advanced or metastatic breast cancer [6].

In this study, we investigated in vitro the effect of Palbociclib in NCI-H295R ACC cells and...

Notes

Acknowledgements

This work was supported by University of Brescia local grants; AIRC, project IG17678; Fondazione Camillo Golgi and by a private donation of Mrs Serena Ambrogini and family in memory of her son Guido Cioni. M.F. was supported by a grant from the Italian Society of Pharmacology. Palbociclib was kindly provided by Pfizer.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest in relation to the topic of the manuscript.

Ethical approval

The project was approved by the local Ethical Committee.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    A. Berruti, E. Baudin, H. Gelderblom, H.R. Haak, F. Porpiglia, M. Fassnacht, G. Pentheroudakis, ESMO guidelines working group: adrenal cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii131–vii138 (2012)Google Scholar
  2. 2.
    A.O. Hoff, A. Berruti, Hormone and Cancer 5th International ACC Symposium: future and current therapeutic trials in adrenocortical carcinoma. Horm. Cancer 7, 29–35 (2016)CrossRefPubMedGoogle Scholar
  3. 3.
    M.C. De Martino, A. Al Ghuzlan, S. Aubert, G. Assié, J.Y. Scoazec, S. Leboulleux, C. Do Cao, R. Libè, C. Nozières, M. Lombès, F. Pattou, F. Borson-Chazot, S. Hescot, C. Mazoyer, J. Young, I. Borget, A. Colao, R. Pivonello, J.C. Soria, J. Bertherat, M. Schlumberger, L. Lacroix, E. Baudin, Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J. Clin. Endocrinol. Metab. 98, 4080–4088 (2013)CrossRefPubMedGoogle Scholar
  4. 4.
    E. Hamilton, J. Infante, Targeting CDK4/6 in patients with cancer. Cancer Treat. Rev. 45, 129–138 (2016)CrossRefPubMedGoogle Scholar
  5. 5.
    M.A. Dickson, Molecular pathways: CDK4 inhibitors for cancer therapy. Clin. Cancer Res. 20, 3379–3383 (2014)CrossRefPubMedGoogle Scholar
  6. 6.
    S. Verma, C.H. Bartlett, P. Schnell, A.M. DeMichele, S. Loi, J. Ro, M. Colleoni, H. Iwata, N. Harbeck, M. Cristofanilli, K. Zhang, A. Thiele, N.C. Turner, H.S. Rugo,: Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III Study (PALOMA-3). Oncologist 21, 1165–1175 (2016)Google Scholar
  7. 7.
    S. Sigala, S. Bodei, C. Missale, D. Zani, C. Simeone, S.C. Cunico, P.F. Spano, Gene expression profile of prostate cancer cell lines: effect of nerve growth factor treatment. Mol. Cell. Endocrinol. 1284, 11–20 (2008)CrossRefGoogle Scholar
  8. 8.
    F. Fiorentini, S. Bodei, F. Bedussi, M. Fragni, S.A. Bonini, C. Simeone, D. Zani, A. Berruti, C. Missale, M. Memo, P.F. Spano, S. Sigala,: GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Exp. Cell Res. 323, 100–111 (2014)Google Scholar
  9. 9.
    I. Casaburi, P. Avena, A. De Luca, A. Chimento, R. Sirianni, R. Malivindi, V. Rago, M. Fiorillo, F. Domanico, C. Campana, A.R. Cappello, F. Sotgia, M.P. Lisanti, V. Pezzi, Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC). Oncotarget 22, 25135–25148 (2015)Google Scholar
  10. 10.
    R. Roskoski, Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol. Res. 107, 249–275 (2016)CrossRefPubMedGoogle Scholar
  11. 11.
    N.J. Dyson, RB1: a prototype tumor suppressor and an enigma. Genes Dev. 30, 1492–1502 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    M. Malumbres, M. Barbacid, Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30, 630–641 (2005)CrossRefPubMedGoogle Scholar
  13. 13.
    G. Assié, E. Letouzé, M. Fassnacht, A. Jouinot, W. Luscap, O. Barreau, H. Omeiri, S. Rodriguez, K. Perlemoine, F. René-Corail, N. Elarouci, S. Sbiera, M. Kroiss, B. Allolio, J. Waldmann, M. Quinkler, M. Mannelli, F. Mantero, T. Papathomas, R. De Krijger, A. Tabarin, V. Kerlan, E. Baudin, F. Tissier, B. Dousset, L. Groussin, L. Amar, E. Clauser, X. Bertagna, B. Ragazzon, F. Beuschlein, R. Libé, A. de Reyniès, J. Bertherat, Integrated genomic characterization of adrenocortical carcinoma. Nat. Genet. 46, 607–612 (2014)CrossRefPubMedGoogle Scholar
  14. 14.
    B. Ragazzon, R. Libé, G. Assié, F. Tissier, O. Barreau, C. Houdayer, K. Perlemoine, A. Audebourg, E. Clauser, F. René-Corail, X. Bertagna, B. Dousset, J. Bertherat, L. Groussin, Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. Eur. J. Endocrinol. 170, 385–391 (2014)CrossRefPubMedGoogle Scholar
  15. 15.
    J.T. Hoffman, A. Plotka, M. O'Gorman, A. Chang, M. Kosa, C.M. Loi, C. Gallo-Stampino, D.D. Wang,: A phase 1 randomized, open-label, fixed-sequence, 2-period study of the effect of multiple doses of rifampin on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers. ASCO Annual Meeting, Philadelphia, 18–22, (2015)Google Scholar
  16. 16.
    D.B. Rivadeneira, C.N. Mayhew, C. Thangavel, E. Sotillo, C.A. Reed, X. Graña, E.S. Knudsen, Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 138, 1920–1930 (2010)CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    M. Fraenkel, M. Gueorguiev, D. Barak, A. Salmon, A.B. Grossman, D.J. Gross, Everolimus therapy for progressive adrenocortical cancer. Endocrine 44, 187–192 (2013)CrossRefPubMedGoogle Scholar
  18. 18.
    M.C. De Martino, P.M. van Koetsveld, R.A. Feelders, S.W. Lamberts, W.W. de Herder, A. Colao, R. Pivonello, L.J. Hofland, Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells. Endocrine 52, 664–667 (2016)CrossRefPubMedGoogle Scholar
  19. 19.
    C. Fiorentini, M. Fragni, P. Perego, S. Vezzoli, S.A. Bonini, M. Tortoreto, D. Galli, M. Claps, G.A. Tiberio, M. Terzolo, C. Missale, M. Memo, G. Procopio, N. Zaffaroni, A. Berruti, S. Sigala, Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: a preclinical study. J. Clin. Endocrinol. Metab. 101, 4594–4602 (2016)CrossRefPubMedGoogle Scholar
  20. 20.
    A. Berruti, M. Terzolo, P. Sperone, A. Pia, S. Della Casa, D.J. Gross, C. Carnaghi, P. Casali, F. Porpiglia, F. Mantero, G. Reimondo, A. Angeli, L. Dogliotti, Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr. Relat. Cancer 12, 657–666 (2005)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Chiara Fiorentini
    • 1
  • Martina Fragni
    • 1
  • Guido A. M. Tiberio
    • 2
  • Diego Galli
    • 1
  • Elisa Roca
    • 3
  • Valentina Salvi
    • 4
  • Daniela Bosisio
    • 4
  • Cristina Missale
    • 1
  • Massimo Terzolo
    • 5
  • Maurizio Memo
    • 1
  • Alfredo Berruti
    • 3
  • Sandra Sigala
    • 1
  1. 1.Section of Pharmacology, Department of Molecular and Translational MedicineUniversity of BresciaBresciaItaly
  2. 2.Surgical Clinic, Department of Clinical and Experimental SciencesUniversity of Brescia at Asst Spedali Civili di BresciaBresciaItaly
  3. 3.Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public HealthUniversity of Brescia at Asst Spedali Civili di BresciaBresciaItaly
  4. 4.Section of Oncology and Experimental Immunology, Department of Molecular and Translational MedicineUniversity of BresciaBresciaItaly
  5. 5.Internal Medicine 1, Department of Clinical and Biological SciencesUniversity of Turin at San Luigi HospitalOrbassanoItaly

Personalised recommendations